Oncodesign will receive an upfront payment of €3 million at the signing of the partnership and could receive up to €320m excluding sales royalties
 |
| Philippe Genne, CEO and founder, Oncodesign |
Servier and Oncodesign have announced a strategic partnership for the research and development of potential drug candidates for Parkinson's disease.
This research and development partnership involves the LRRK2 kinase inhibitors derived from Oncodesign's proprietary Nanocyclix platform and their potential to act as therapeutic agents against Parkinson's disease.
The partnership draws on the complementary expertise of Servier and Oncodesign in the field of neurodegenerative diseases and macrocyclic kinase inhibitors.
"This partnership is a result of the choices and investments that we have made during the past 18 months to put together a portfolio of promising drug candidates derived from our Nanocyclix platform. The pharmaceutical industry is currently showing a keen interest in new treatments for Parkinson's disease, particularly around LRRK2 kinase, which is considered as a high-potential target to treat this disease."
"Servier's expertise will be a key asset in the early stage of this research agreement with regard to successfully running the programme, which, in the medium term, could lead to the development of new drug candidates," said Philippe Genne, CEO and founder of Oncodesign.
Christophe Thurieau, Director of Servier's research centres, said: "We are thrilled to be collaborating with Oncodesign to work towards our common goal of developing a treatment for Parkinson's disease."
Oncodesign’s expertise in LRRK2 kinase inhibitors sets it apart; it could become a treatment of choice. This partnership between Oncodesign and Servier combines a strong synergy between the proven know-how of a biopharmaceutical company and the expertise of an international pharmaceutical group."
Companies
https://www.manufacturingchemist.com/news/article_page/Servier_and_Oncodesign_join_forces_to_investigate_new_Parkinsons_drug/152666
No comments:
Post a Comment